{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-23-000047","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-07-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.010613+00:00","generated_at":"2026-06-13T09:41:55.461667+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Neurocrine appoints Christine Poon to board; bylaws amended to increase board to 10","bullets":["Christine A. Poon appointed as Class I director effective July 11, 2023, term until 2024 annual meeting.","Poon receives $60k annual cash retainer and option for 16,375 shares (~$800k Black-Scholes) vesting over 3 years.","Board size increased from 9 to 10 via amendment to Section 3.2 of Bylaws.","Poon previously served as Vice Chairman of Johnson & Johnson and Dean at Ohio State Fisher College of Business."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-23-000047","json":"https://secwatch.observer/filing/0000914475-23-000047.json","markdown":"https://secwatch.observer/filing/0000914475-23-000047.md","text":"https://secwatch.observer/filing/0000914475-23-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000047/0000914475-23-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000047/nbix-20230711.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T09:41:55.461667+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ff6e377709","claim":"Christine A. Poon was appointed as Director at NEUROCRINE BIOSCIENCES INC.","evidence_excerpt":"On July 11, 2023, the Board of Directors (the “Board”) of Neurocrine Biosciences, Inc., a Delaware corporation (“Neurocrine”), upon the recommendation of its Nominating / Corporate Governance Committee, appointed Christine A. Poon as a member of the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000047/0000914475-23-000047-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"2928d60931ff59c289ad101473e947ed5af98579","claim":"NEUROCRINE BIOSCIENCES INC: Amended Section 3.2 of Bylaws to increase board size from nine to ten members (effective 2023-07-11).","evidence_excerpt":"On July 11, 2023, the Board amended Section 3.2 of Neurocrine’s Bylaws, as amended and restated (the “Bylaws”), to provide that the Board shall consist of ten members.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000047/0000914475-23-000047-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-07-11"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}